NCT06127381View on ClinicalTrials.gov

An Open-label Study of the Safety and Pharmacokinetics of the TGKP

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
DRUG

Glycolic acid tetrasubstituted piceatannol (TGKP)

A total of 25 volunteers will be randomized and receive the study drug, of which 5 - will receive ¼ therapeutic dose, 5 - will receive ½ therapeutic dose, 15 - will receive the full therapeutic dose.

All Listed Sponsors
lead

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

OTHER